TY - JOUR T1 - Early and long-term risk of new-onset atrial fibrillation after transient ischemic attack JF - medRxiv DO - 10.1101/2021.03.05.21253024 SP - 2021.03.05.21253024 AU - Francisco Purroy AU - Mikel Vicente-Pascual AU - Gloria Arque AU - Mariona Baraldes-Rovira AU - Robert Begue AU - Joan Farre AU - Yhovany Gallego AU - M. Pilar Gil-Villar AU - Gerard Mauri AU - Nuria Montalà AU - Miriam Paul-Arias AU - Cristina Pereira AU - Coral Torres-Querol AU - Daniel Vazquez-Justes Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/08/2021.03.05.21253024.abstract N2 - Background Transient ischemic attack (TIA) provides a unique opportunity to optimize secondary preventive treatments to avoid subsequent ischemic stroke (IS). Although atrial fibrillation (AF) is the leading cause of cardioembolism in IS and anticoagulation prevents stroke recurrence (SR), limited data exists about the risk of new-onset AF after TIA.Methods We carried out a prospective cohort study of consecutive patients with TIA from January 2006 to June 2010. The risk of new diagnosis of AF and SR was defined after a median follow-up time of 6.5 (5.0-9.6) years. In a subgroup of consecutive patients, a panel of biomarkers was assessed during the first 24 h of the onset of symptoms.Results 723 TIA patients were included. New-onset AF was diagnosed in 116 (16.0%) patients, 42 (36.2%) of them during admission. 204 (28.2%) patients were included in the biomarker substudy. New-onset AF was associated with sex (female) (hazard ratio [HR] 1.61 [95% CI, 1.07-2.41]), age (HR 1.05 [95% CI, 1.03-1.07]), previous ischemic heart disease (HR 1.84 [95% CI 1.15-2.97]) and cortical DWI pattern (HR 2.81 [95% CI 1.87-4.21]). In the Kaplan-Meier analysis, NT-proBNP ≥218.2 pg/ml (log-rank test P<0.001) was associated with significant risk of new-onset AF during the first five years of follow-up. Patients with a new diagnosis of AF after admission and before five years of follow-up had the highest risk of SR (P=0.002).Conclusion The risk of new diagnosis of AF after TIA is clinically relevant. We identified clinical, neuroimaging and biomarker predictors of new-onset AF.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Catalan Autonomous Government s Agencia de Gestio d Ajuts Universitaris i de Recerca (2017 suport a les activitats dels grups de recerca 1628) and the Instituto de Salud Carlos III, (08/1398, 11/02033 and 14/01574) and the INVICTUS plus Research Network. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent or assent from relatives was obtained for all the participants. The study was approved by our local Ethics Committee: the Comite d Etica i Investigacio Clinica de l Hospital Universitari Arnau de Vilanova de LleidaAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for access to the data reported in this article will be considered by the corresponding author. ER -